Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma

被引：0
|
作者：
Ravi Potluri
Sandip Ranjan
Hitesh Bhandari
Helen Johnson
Andriy Moshyk
Srividya Kotapati
机构：
[1] SmartAnalyst Inc.,
[2] SmartAnalyst India Pvt. Ltd.,undefined
[3] Bristol-Myers Squibb,undefined
[4] Bristol-Myers Squibb,undefined
来源：
Experimental Hematology & Oncology | / 8卷
关键词：
Advanced melanoma; Melanoma; Nivolumab; Ipilimumab; Healthcare cost comparison; CheckMate 067; NCT01844505;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Cost-effectiveness of nivolumab in combination with ipilimumab in patients with unresectable advanced melanoma in Australia
    Bohensky, M. A.
    Kim, H.
    Gorelik, A.
    Liew, D.
    ANNALS OF ONCOLOGY, 2015, 26 : 103 - 103
  • [32] Updated analysis of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma
    Takahashi, Akira
    Namikawa, Kenjiro
    Ogata, Dai
    Jinnai, Shunichi
    Nakano, Eiji
    Yamazaki, Naoya
    JOURNAL OF DERMATOLOGY, 2023, 50 (04): : 525 - 535
  • [33] Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis
    Jiang, Huihui
    Xu, Aiqun
    Xia, Wanli
    Xia, Xingyuan
    Li, Pulin
    Zhang, Binbin
    Zhu, Ke
    Zhou, Sijing
    Wang, Ran
    CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [34] Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis
    Huihui Jiang
    Aiqun Xu
    Wanli Xia
    Xingyuan Xia
    Pulin Li
    Binbin Zhang
    Ke Zhu
    Sijing Zhou
    Ran Wang
    Cancer Cell International, 21
  • [35] Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma
    Ugurel, Selma
    Kiecker, Felix
    Froehling, Stefan
    Wetter, Axel
    Bankfalvi, Agnes
    Sucker, Antje
    Zimmer, Lisa
    Livingstone, Elisabeth
    Roesch, Alexander
    Becker, Juergen C.
    Schadendorf, Dirk
    EUROPEAN JOURNAL OF CANCER, 2017, 83 : 142 - 145
  • [36] Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials
    Menshawy, Amr
    Eltonob, Abdelrahman A.
    Barkat, Sarah A.
    Ghanem, Ahmed
    Mniesy, Mahmoud M.
    Mohamed, Ishak
    Abdel-Maboud, Mohamed
    Mattar, Omar M.
    Elfil, Mohamed
    Bahbah, Eshak I.
    Elgebaly, Ahmed
    MELANOMA RESEARCH, 2018, 28 (05) : 371 - 379
  • [37] Real-world use of ipilimumab and nivolumab monotherapy or in combination in patients with advanced melanoma: results from a retrospective chart review
    Tarhini, A.
    Macahilig, C.
    Atzinger, C.
    Gupte-Singh, K.
    Solem, C.
    Rao, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [38] Nico: Real World Evidence in Advanced Melanoma; A National Prospective Non-Interventional Study of Nivolumab Monotherapy or in Combination with Ipilimumab in Patients with Advanced Melanoma and in Patients with Adjuvant Nivolumab Therapy
    Schadendorf, Dirk
    Eigertler, Thomas
    Mohr, Peter
    Weichenthal, Michael
    Goeppner, Daniela
    Haferkamp, Sebastian
    Herber, Martin
    Meier, Friedegund
    Meiss, Frank
    Pfoehler, Claudia
    Schneider, Stefan W.
    Terheyden, Patrick
    Ulrich, Lens
    Utikal, Jochen
    Weishaupt, Carsten
    Gutzmer, Ralf
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 175 - 175
  • [39] Nivolumab plus ipilimumab in the treatment of advanced melanoma
    Tsai, Katy K.
    Daud, Adil I.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [40] Nivolumab plus ipilimumab in the treatment of advanced melanoma
    Katy K. Tsai
    Adil I. Daud
    Journal of Hematology & Oncology, 8
12345